General Electric Co. is selling a portion of its life sciences unit to Danaher Corp., the conglomerate formerly led by current GE CEO Larry Culp, for $21.4 billion, the company said Monday.
GE (NYSE: GE) is sending Danaher (NYSE: DHR) its BioPharma business, which focuses on software and instruments related to the creation of biopharmaceutical drugs. The business generated approximately $3 billion in revenue for GE last year, as one part of GE’s larger life sciences and health care business.
